Revuforj (revumenib) — Medica
acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation
Initial criteria
- Patient is age ≥ 1 year
- Patient has relapsed disease OR refractory disease
- Disease is positive for a lysine methyltransferase 2A (KMT2A) gene translocation
Approval duration
1 year